Tazemetostat, a selective inhibitor of EZH2, was the first compound of this class that was approved by the FDA for the treatment of locally advanced epitheloid sarcoma and follicular lymphoma in 2020 [138,139] (Figure 3). Here, EZH2 is linked to follicular lymphoma.